Role of ubiquitin-specific proteases in hepatocellular carcinoma

Yi TANG; Guotai WANG; Yuhan JIANG

doi:10.12449/JCH250525

Volume 41 Issue 5

May 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(5): 968-974

PDF( 983 KB)

Role of ubiquitin-specific proteases in hepatocellular carcinoma

DOI: 10.12449/JCH250525

Yi TANG¹,
Guotai WANG^{2
,
,
,},
Yuhan JIANG¹

1.
The First Clinical Medical College，Shaanxi University of Chinese Medicine，Xianyang，Shaanxi 712046，China
2.
Department of Hepatobiliary Surgery，The Affiliated Hospital of Shaanxi University of Chinese Medicine，Xianyang，Shaanxi 712099，China

Research funding:

Shaanxi Administration of Traditional Chinese Medicine (SZY-KJCYC-2025-JC-004);

Qinchuangyuan Traditional Chinese Medicine Industry Innovation Cluster Project (L2024-QCY-ZYYJJQ-Y09);

Project for Young and Middle-aged Science and Technology Leaders in Xianyang City (L2022CXNLRC018);

Xianyang Science and Technology Bureau (2021ZDYF-SF-0037)

More Information

Corresponding author: WANG Guotai， wangtai_52@126.com （ORCID： 0009-0009-5405-9351）
Received Date: 2024-09-13
Accepted Date: 2024-11-08
Published Date: 2025-05-25

Abstract

Abstract

Hepatocellular carcinoma （HCC） is a common primary malignant tumor. In recent years， the role of ubiquitin-specific proteases （USPs） in HCC has attracted widespread attention. USPs are a class of key deubiquitinating enzymes that affect a variety of biological processes by regulating the ubiquitination status of proteins. Studies have shown that USPs participate in the regulation of cell proliferation， apoptosis， migration， and invasion by deubiquitinating various tumor-related proteins. In addition， the abnormal expression of USPs is closely associated with the prognosis of HCC patients and may thus be used as potential biomarkers and therapeutic targets. This article reviews the research advances in USPs in HCC and explores their key roles in the development， progression， and metastasis of HCC. A deep understanding of the mechanism of action of USPs in HCC not only helps to reveal the pathogenesis of HCC， but also provides a scientific basis for developing new diagnostic tools and treatment strategies. Future research should further explore the regulatory effect of USPs in HCC， in order to provide more effective means for the clinical treatment of HCC.
- Carcinoma， Hepatocellular,
- Ubiquitin-Specific Proteases,
- Enzyme Inhibitors

FullText(HTML)

References(48)

References

[1]	SIEGEL RL, MILLER KD, WAGLE NS, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73( 1): 17- 48. DOI: 10.3322/caac.21763.
[2]	National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
[3]	ÇETIN G, KLAFACK S, STUDENCKA-TURSKI M, et al. The ubiquitin-proteasome system in immune cells[J]. Biomolecules, 2021, 11( 1): 60. DOI: 10.3390/biom11010060.
[4]	LIU DY, LI QH, ZANG YF, et al. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis[J]. Cell Death Dis, 2023, 14( 4): 264. DOI: 10.1038/s41419-023-05777-1.
[5]	XIONG B, HUANG JW, LIU Y, et al. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A[J]. Cell Oncol(Dordr), 2021, 44( 2): 329- 343. DOI: 10.1007/s13402-020-00568-8.
[6]	LI TY, YAN B, MA Y, et al. Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination[J]. Cell Death Dis, 2018, 9( 2): 148. DOI: 10.1038/s41419-017-0182-5.
[7]	QIU C, LIU Y, MEI Y, et al. Ubiquitin-specific protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-β signaling-induced epithelial-mesenchymal transition[J]. Aging(Albany NY), 2018, 10( 10): 2783- 2799. DOI: 10.18632/aging.101587.
[8]	YAN BK, GUO JX, WANG ZL, et al. The ubiquitin-specific protease 5 mediated deubiquitination of LSH links metabolic regulation of ferroptosis to hepatocellular carcinoma progression[J]. MedComm(2020), 2023, 4( 4): e337. DOI: 10.1002/mco2.337.
[9]	MENG J, AI XY, LEI YY, et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma[J]. Theranostics, 2019, 9( 2): 573- 587. DOI: 10.7150/thno.27654.
[10]	GEORGES A, MARCON E, GREENBLATT J, et al. Author correction: Identification and characterization of USP7 targets in cancer cells[J]. Sci Rep, 2019, 9: 15664. DOI: 10.1038/s41598-019-43448-4.
[11]	SU C, ZHANG HQ, MO J, et al. SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation[J]. Clin Transl Med, 2024, 14( 1): e1563. DOI: 10.1002/ctm2.1563.
[12]	TANG JN, LONG G, XIAO L, et al. USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilization[J]. Cell Death Dis, 2023, 14( 6): 360. DOI: 10.1038/s41419-023-05747-7.
[13]	YUAN T, CHEN ZB, YAN FJ, et al. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein[J]. Mol Oncol, 2020, 14( 1): 197- 210. DOI: 10.1002/1878-0261.12596.
[14]	ZHU H, YAN FJ, YUAN T, et al. USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZ[J]. Cancer Res, 2020, 80( 11): 2204- 2216. DOI: 10.1158/0008-5472.CAN-19-2388.
[15]	CHEN J, NING D, DU PC, et al. USP11 potentiates HGF/AKT signaling and drives metastasis in hepatocellular carcinoma[J]. Oncogene, 2024, 43( 2): 123- 135. DOI: 10.1038/s41388-023-02847-8.
[16]	QIAO LJ, HU WB, LI LZ, et al. USP11 promotes glycolysis by regulating HIF-1α stability in hepatocellular carcinoma[J]. J Cell Mol Med, 2024, 28( 2): e18017. DOI: 10.1111/jcmm.18017.
[17]	LUO CH, LU YY, FANG QL, et al. TRIM55 restricts the progression of hepatocellular carcinoma through ubiquitin-proteasome-mediated degradation of NF90[J]. Cell Death Discov, 2024, 10( 1): 441. DOI: 10.1038/s41420-024-02212-y.
[18]	LIU CS, LI XN, FENG G, et al. Downregulation of USP12 inhibits tumor growth via the p38/MAPK pathway in hepatocellular carcinoma[J]. Mol Med Rep, 2020, 22( 6): 4899- 4908. DOI: 10.3892/mmr.2020.11557.
[19]	GAO S, CHEN TX, LI LJ, et al. Hypoxia-inducible ubiquitin specific peptidase 13 contributes to tumor growth and metastasis via enhancing the toll-like receptor 4/myeloid differentiation primary response gene 88/nuclear factor-κB pathway in hepatocellular carcinoma[J]. Front Cell Dev Biol, 2020, 8: 587389. DOI: 10.3389/fcell.2020.587389.
[20]	ZHANG NN, ZHANG H, YANG XB, et al. USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis[J]. BMC Cancer, 2024, 24( 1): 237. DOI: 10.1186/s12885-024-12009-y.
[21]	LV C, WANG SL, LIN L, et al. USP14 maintains HIF1-α stabilization via its deubiquitination activity in hepatocellular carcinoma[J]. Cell Death Dis, 2021, 12( 9): 803. DOI: 10.1038/s41419-021-04089-6.
[22]	TIAN ZL, XU C, HE WX, et al. The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP[J]. Cancer Lett, 2023, 577: 216439. DOI: 10.1016/j.canlet.2023.216439.
[23]	LI WJ, CUI KS, PROCHOWNIK EV, et al. The deubiquitinase USP21 stabilizes MEK2 to promote tumor growth[J]. Cell Death Dis, 2018, 9( 5): 482. DOI: 10.1038/s41419-018-0523-z.
[24]	JING TT, WANG BS, YANG ZJ, et al. Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma[J]. Cancer Lett, 2021, 518: 266- 277. DOI: 10.1016/j.canlet.2021.07.044.
[25]	LING SB, SHAN QN, ZHAN QF, et al. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation[J]. Gut, 2020, 69( 7): 1322- 1334. DOI: 10.1136/gutjnl-2019-319616.
[26]	LIU YH, MA JJ, LU SM, et al. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway[J]. Chin Med J(Engl), 2023, 136( 18): 2229- 2242. DOI: 10.1097/CM9.0000000000002714.
[27]	ZOU TT, WANG Y, DONG L, et al. Stabilization of SETD3 by deubiquitinase USP27 enhances cell proliferation and hepatocellular carcinoma progression[J]. Cell Mol Life Sci, 2022, 79( 1): 70. DOI: 10.1007/s00018-021-04118-9.
[28]	GAO RZ, BUECHEL D, KALATHUR RKR, et al. USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis[J]. Oncogenesis, 2021, 10( 7): 52. DOI: 10.1038/s41389-021-00338-7.
[29]	LV T, ZHANG B, JIANG CH, et al. USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination-mediated degradation[J]. Int J Oncol, 2023, 63( 4): 113. DOI: 10.3892/ijo.2023.5561.
[30]	WANG LP, WANG JW, MA XQ, et al. USP35 promotes HCC development by stabilizing ABHD17C and activating the PI3K/AKT signaling pathway[J]. Cell Death Discov, 2023, 9( 1): 421. DOI: 10.1038/s41420-023-01714-5.
[31]	DONG X, LIU ZX, ZHANG EC, et al. USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma[J]. Cell Signal, 2021, 85: 110068. DOI: 10.1016/j.cellsig.2021.110068.
[32]	MO HY, LI RT, YANG N, et al. USP40 promotes hepatocellular carcinoma progression through a YAP/USP40 positive feedback loop[J]. Cancer Lett, 2024, 589: 216832. DOI: 10.1016/j.canlet.2024.216832.
[33]	QIU YM, HUANG D, SHENG YL, et al. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1[J]. Exp Cell Res, 2021, 405( 1): 112646. DOI: 10.1016/j.yexcr.2021.112646.
[34]	HUANG P, WANG YH, ZHANG PF, et al. Ubiquitin-specific peptidase 1: Assessing its role in cancer therapy[J]. Clin Exp Med, 2023, 23( 7): 2953- 2966. DOI: 10.1007/s10238-023-01075-4.
[35]	CHEN SP, ZHU GQ, XING XX, et al. LncRNA USP2-AS1 promotes hepatocellular carcinoma growth by enhancing YBX1-mediated HIF1α protein translation under hypoxia[J]. Front Oncol, 2022, 12: 882372. DOI: 10.3389/fonc.2022.882372.
[36]	CAO YQ, XIA H, TAN XY, et al. Intratumoural microbiota: A new frontier in cancer development and therapy[J]. Signal Transduct Target Ther, 2024, 9( 1): 15. DOI: 10.1038/s41392-023-01693-0.
[37]	LU C, NING Z, WANG AM, et al. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma[J]. Cancer Lett, 2018, 436: 139- 148. DOI: 10.1016/j.canlet.2018.07.032.
[38]	YE QW, ZHOU W, XU SJ, et al. Ubiquitin-specific protease 22 promotes tumorigenesis and progression by an FKBP12/mTORC1/autophagy positive feedback loop in hepatocellular carcinoma[J]. MedComm(2020), 2023, 4( 6): e439. DOI: 10.1002/mco2.439.
[39]	NING Z, GUO X, LIU XL, et al. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma[J]. Nat Commun, 2022, 13( 1): 2187. DOI: 10.1038/s41467-022-29846-9.
[40]	GUO JH, ZHAO J. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma[J]. Biochim Biophys Acta Mol Cell Res, 2024, 1871( 1): 119617. DOI: 10.1016/j.bbamcr.2023.119617.
[41]	ZENG K, XIE WW, WANG CY, et al. USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma[J]. Cell Death Dis, 2023, 14( 3): 194. DOI: 10.1038/s41419-023-05699-y.
[42]	CHANG YS, SU CW, CHEN SC, et al. Upregulation of USP22 and ABCC1 during sorafenib treatment of hepatocellular carcinoma contribute to development of resistance[J]. Cells, 2022, 11( 4): 634. DOI: 10.3390/cells11040634.
[43]	GAO HL, XI Z, DAI JW, et al. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases(USPs) in cancers: New directions and therapeutic options[J]. Mol Cancer, 2024, 23( 1): 88. DOI: 10.1186/s12943-024-02005-y.
[44]	CHEN SS, ZHOU BH, HUANG W, et al. The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression[J]. Cell Death Dis, 2023, 14( 12): 830. DOI: 10.1038/s41419-023-06358-y.
[45]	ZHOU WH, CHEN JF, WANG JG. Comprehensive prognostic and immunological analysis of Ubiquitin Specific Peptidase 28 in pan-cancers and identification of its role in hepatocellular carcinoma cell lines[J]. Aging(Albany NY), 2023, 15( 13): 6545- 6576. DOI: 10.18632/aging.204869.
[46]	LEI H, XU HZ, SHAN HZ, et al. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia[J]. Nat Commun, 2021, 12( 1): 51. DOI: 10.1038/s41467-020-20259-0.
[47]	LU Y, GAO J, WANG PP, et al. Discovery of potent small molecule ubiquitin-specific protease 10 inhibitors with anti-hepatocellular carcinoma activity through regulating YAP expression[J]. Eur J Med Chem, 2024, 272: 116468. DOI: 10.1016/j.ejmech.2024.116468.
[48]	LARSSON P, OLSSON M, SARATHCHANDRA S, et al. Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers[J]. Sci Rep, 2024, 14( 1): 18576. DOI: 10.1038/s41598-024-62339-x.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (486) PDF downloads(35)

Role of ubiquitin-specific proteases in hepatocellular carcinoma

DOI: 10.12449/JCH250525

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of ubiquitin-specific proteases in hepatocellular carcinoma

DOI: 10.12449/JCH250525

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content